Advertisement
Loading...

Virax Biolabs Group Limited

VRAX•NASDAQ
Healthcare
Biotechnology
$0.25
$0.09(61.37%)
U.S. Market opens in 16h 28m

Virax Biolabs Group Limited (VRAX) Stock Overview

Explore Virax Biolabs Group Limited’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap1.1M
P/E Ratio-0.12
EPS (TTM)$-1.22
ROE-1.03%
Fundamental Analysis

AI Price Forecasts

1 Month$-0.06
3 Months$0.00
1 Year Target$0.00

VRAX Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Virax Biolabs Group Limited (VRAX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of C+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 50.24, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.00.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.12 and a market capitalization of 1.1M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
61.37%
5-Day Change
76.93%
1-Month Change
65.24%
3-Month Change
13.62%
6-Month Change
-45.05%
Year-to-Date (YTD) Change
-28.37%
1-Year Change
-76.85%
3-Year Change
-94.16%
5-Year Change
-99.86%
All-Time (Max) Change
-99.86%

Contact Information

https://viraxbiolabs.com
44 20 7788 7414
30 Broadwick Street, London, NaN, W1F 8LX

Company Facts

17 Employees
IPO DateJul 21, 2022
CountryGB
Actively Trading

Frequently Asked Questions